AI to accelerate Novo Nordisk’s Parkinson’s cell therapy

By 2026-05-12T11:32:00

lewy bodies parkinson's

Source:

Cellular Intelligence’s AI-native platform to compress traditional process development for the pluripotent stem cell-derived dopaminergic progenitor therapy.

Novo Nordisk has granted Cellular Intelligence rights to its cell therapy programme for Parkinson’s, who under the agreement, will apply its AI foundation model to optimise and scale its development.

Cellular Intelligence’s technology is set to reduce traditional cell therapy process development and manufacturing timelines and streamline the path to commercialisation. The model is trained on data spanning

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member